Cost-effectiveness analysis of trastuzumab deruxtecan versus ramucirumab plus paclitaxel as second-line treatment for HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

Related documents

• Force-Induced Control of Circularly Polarized Luminescence With Rotaxane Architecture.#1054380
• Dental school caries and periodontitis risk analysis skillset: survey of carryover to practice.#1054381
• Maternal and child health challenges during and after flooding: a qualitative study in Makassar, Indonesia.#1054382
• Genetic diversity of Camelina sativa: implications for sustainable crop improvement through Genotyping-by-Sequencing (GBS).#1054383
• 'Poverty is the biggest barrier': stakeholder perspectives on social determinants of malaria in Wakiso District, Uganda.#1054384